Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2024 | Treatment updates in ALS: edaravone, AMX0035, and tofersen

Jinsy Andrews, MD, FAAN, Columbia University, New York, NY, gives an overview of treatments for amyotrophic lateral sclerosis (ALS) that have gained approval in the last few years. She mentions two therapies that were FDA-approved in 2022: edaravone and AMX0035 (sodium phenylbutyrate/taurursodiol). Additionally, tofersen, the first gene therapy for SOD1-ALS, gained approval in 2023. However, following unsuccessful results from the confirmatory Phase III trial (NCT05021536), AMX0035 is set to be withdrawn from the market. Dr Andrews highlights that, although this withdrawal is disappointing, it shows that the regulatory process works. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.